Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Principal Financial Group Inc. decreased its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 11.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 10,316 shares of the biotechnology company’s stock after selling 1,325 shares during the period. Principal Financial Group Inc.’s holdings in Aurinia Pharmaceuticals were worth $93,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of AUPH. Blue Trust Inc. lifted its stake in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 6,174 shares in the last quarter. FMR LLC lifted its stake in Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $108,000. BNP Paribas Financial Markets lifted its stake in Aurinia Pharmaceuticals by 172.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 20,324 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC bought a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $248,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Down 0.5 %

NASDAQ:AUPH opened at $8.15 on Friday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -54.33 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The stock’s 50 day moving average price is $8.08 and its two-hundred day moving average price is $7.88.

Insider Buying and Selling

In related news, insider Greg Keenan sold 8,305 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the transaction, the insider now directly owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. The trade was a 5.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the transaction, the chief executive officer now directly owns 1,953,892 shares in the company, valued at $15,631,136. The trade was a 9.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.